Opis Europe European Clinical Cro

  • Home Cover
Despite COVID-19
OPIS is able to ensure business activity with its client and stakeholders.
Distant but united we continue to work together for clinical research.
Opis is an European clinical cro and it is the best solution for your trials

Clinical CRO - full service

OPIS: In the front line in the fight against COVID-19

The spread of Coronavirus continues both in Italy and globally.

For this reason, in order to protect the health of its employees and at the same time prevent the spread of the virus as much as possible, OPIS promptly adopted multiple precautionary measures for all its employees , in compliance with the Ministerial Decree  issued on March 22, 2020.

Thanks to the measures introduced, OPIS can ensure its business continuity in line with government directives, guaranteeing 100% of all offered services through smart-working and REM activities.

At this time of great difficulty on a global level, OPIS is at the forefront of the fight against Coronavirus, collaborating in studies with the aim of testing new therapeutic approaches in patients with COVID-19 who develop respiratory complications.

OPIS has always made available all its know-how, its experience and professionalism so that its partners can be supported in the clinical development of drugs quickly and in compliance with the provisions in force.

Distant but united we are ready to face with you new and challenging projects to optimize valid therapies to be implemented against COVID-19.


Clinical Research Solutions


Oncology Oncology
Hematology Hematology
Cardiovascular Diseases Cardiovascular Diseases
Neurology Neurology
Respiratory Diseases Respiratory Diseases
Rheumatology Rheumatology
Immunology and Transplantation Immunology and Transplantation
Metabolism and Nutritional Disorders Metabolism and Nutritional Disorders
Ophthalmology Ophthalmology

In 21 years of combining medical, regulatory, statistical and technological expertise, OPIS has assisted over 40 different clients with interventional and non-interventional clinical trials. Full service projects in a wide range of therapeutic areas include various rare disease indications as well as pediatric studies. Currently, over 40% of trials managed by OPIS are oncology or onco-hematology trials. Other major therapeutic areas include ophthalmology, neurology and cardiology. OPIS has established collaboration with numerous international Sponsors on multi-country trials. In addition to phase I-IV drug-related trials, OPIS also holds experience in managing clinical investigations for medical and diagnostic devices and in nutraceutical/food supplement studies.